# OCGN catalysts: Ocugen, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ocgn/catalysts

> Ocugen, Inc. (OCGN) has 11 upcoming catalysts. The next is the Ocugen, Inc. topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for OCGN?

Ocugen, Inc. (OCGN) has 11 upcoming catalysts. The next is the Ocugen, Inc. topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "Top-line data from the 140-patient Phase 3 liMeliGhT trial are expected in the first quarter of 2027, followed by a planned Biologics" [Calendar and source filings](https://sec-api.dev/companies/ocgn/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-122401, https://www.sec.gov/Archives/edgar/data/1372299/000110465926122401/tm2628896d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/companies/ocgn/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Ocugen, Inc. |
| Ticker | OCGN (Nasdaq) |
| SEC CIK | 1372299 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/ocgn |

## Cash runway

Cash $84.3M as of 2026-09-30; quarterly burn $15.7M; about 16.1 months of runway at that rate (XBRL company facts, accession 0001628280-26-069835).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2024 | [OCU400 FDA approval](https://sec-api.dev/pdufa/ocu400) | OCGN |  | completed, approved | "In August 2024, we received approval from the FDA to begin our expanded access program (EAP) for the treatment of adult patients, aged 18 or older, with RP." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1372299/000162828024047846/ocgn-20240930.htm)) |
| Jan 2025 | [OCU200 trial start](https://sec-api.dev/pdufa/ocu200) | OCGN |  | completed | "The first subject was dosed in the OCU200 multicenter open label Phase 1 clinical trial in January 2025, and we are actively recruiting subjects." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926005452/tm263710d1_424b5.htm)) |
| March 5, 2025 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "MALVERN, PA, March 5, 2025 (GLOBE NEWSWIRE) - Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported fourth quarter and full year 2024 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000162828025010245/ocgn-20250305xex991.htm)) |
| Q2 2025 | [OCU500 trial start](https://sec-api.dev/pdufa/ocu500) | OCGN |  | scheduled | "Finally, the Investigational New Drug application is in effect for OCU500, and the National Institute of Allergy and Infectious Diseases intends to initiate a Phase 1 clinical trial in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000162828025024095/ocgn20250509ex991.htm)) |
| May 9, 2025 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025 MALVERN, Pa., May 9, 2025 GLOBE NEWSWIRE) - Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported first quarter 2025 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000162828025024095/ocgn20250509ex991.htm)) |
| August 1, 2025 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "(Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported second quarter 2025 financial results along with a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465925072992/tm2522209d1_ex99-1.htm)) |
| November 5, 2025 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported third quarter 2025 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465925106664/tm2530208d1_ex99-1.htm)) |
| 2026 | [OCU400 interim data readout](https://sec-api.dev/pdufa/ocu400) | OCGN |  | scheduled | "Intend to release interim data (50% of patients at 8 months of treatment) mid-year 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465925106664/tm2530208d1_ex99-1.htm)) |
| Mar 2026 | [OCU410 topline data readout](https://sec-api.dev/pdufa/ocu410) | OCGN |  | completed, positive | "In March 2026, we announced positive 12-month topline data from the Phase 2 ArMaDa clinical trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926054866/tm2613474d1_ex99-1.htm)) |
| Mar 2026 | [OCU410 NDA/BLA submission](https://sec-api.dev/pdufa/ocu410) | OCGN |  | scheduled | "Rolling Submission * Market Authorization Application will follow BLA submission Ocugen - March 2026 Phase 3 Enrollment Completed" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000162828026021541/corporatedeck_march26x20.htm)) |
| March 4, 2026 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "Pa, March 4, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported fourth quarter and full year 2025 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926023288/tm267731d1_ex99-1.htm)) |
| Q2 2026 | [OCU500 trial start](https://sec-api.dev/pdufa/ocu500) | OCGN |  | scheduled | "NIAID intends to initiate the OCU500 Phase 1 clinical trial in the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926055411/tm2613584d1_ex99-1.htm)) |
| May 5, 2026 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported first quarter 2026 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926055411/tm2613584d1_ex99-1.htm)) |
| Q3 2026 | [Ocugen, Inc. interim data readout](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | scheduled | "Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the second quarter 2027 in advance of the BLA submission." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926023288/tm267731d1_ex99-1.htm)) |
| Q3 2026 | [OCU410 topline data readout](https://sec-api.dev/pdufa/ocu410) | OCGN |  | scheduled | "Upcoming Global Phase 3 , n=~300, adaptive design, >95% power, 3Q 2026 (Target) Ocugen - OCU410 Phase 2 Topline Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926033724/tm269664d1_ex99-2.htm)) |
| Q3 2026 | [OCU410 trial start](https://sec-api.dev/pdufa/ocu410) | OCGN |  | scheduled | "The Company plans to initiate the OCU410 Phase 3 registrational trial in the third quarter of 2026 with potential BLA filing by 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926055411/tm2613584d1_ex99-1.htm)) |
| Q3 2026 | [OCU400 NDA/BLA submission](https://sec-api.dev/pdufa/ocu400) | OCGN |  | scheduled | "The Company plans to initiate the rolling BLA submission for OCU400 in the third quarter of 2026 and complete the BLA submission by the second quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926055411/tm2613584d1_ex99-1.htm)) |
| August 6, 2026 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported second quarter 2026 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/tm2622368d1_ex99-1.htm)) |
| September 1, 2026 | [OCU410 trial start](https://sec-api.dev/pdufa/ocu410) | OCGN |  | completed | "On September 1, 2026, the Company announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for Geographic Atrophy ("GA") secondary to dry age-related macular degeneration ("dAMD")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1372299/000110465926105968/tm2624985d1_8k.htm)) |
| Sep to Dec 2026 | [OCU410ST topline data readout](https://sec-api.dev/pdufa/ocu410st) | OCGN | Stargardt Disease | scheduled | "NCT05956626 (A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-09-28 (ESTIMATED); Lead Sponsor Ocugen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05956626)) |
| September 2026 | [OCU410ST primary completion](https://sec-api.dev/pdufa/ocu410st) | OCGN | Stargardt Disease | delayed | "NCT05956626 (A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-09-28 (ESTIMATED); Lead Sponsor Ocugen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05956626)) |
| Q4 2026 | [OCU400 topline data readout](https://sec-api.dev/pdufa/ocu400) | OCGN |  | scheduled | "Intend to initiate BLA rolling submission in the first half of 2026 and release Phase 3 top-line data in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465925106664/tm2530208d1_ex99-1.htm)) |
| November 4, 2026 | [OCU410 trial start](https://sec-api.dev/pdufa/ocu410) | OCGN |  | completed | "Announced the first patient dosed in ArMaDa3, a 240-subject global Phase 3 trial randomizing patients 2:1 to a single subretinal injection of OCU410 or untreated control across the U.S., Canada, and Europe; the primary endpoint is GA lesion growth over 12 months" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926122401/tm2628896d1_ex99-1.htm)) |
| November 4, 2026 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported third quarter 2026 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926122401/tm2628896d1_ex99-1.htm)) |
| Q1 2027 | [Ocugen, Inc. topline data readout](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | scheduled | "Top-line data from the 140-patient Phase 3 liMeliGhT trial are expected in the first quarter of 2027, followed by a planned Biologics" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926122401/tm2628896d1_ex99-1.htm)) |
| Q1 2027 | [OCU400 NDA/BLA submission](https://sec-api.dev/pdufa/ocu400) | OCGN |  | scheduled | "3 liMeliGhT clinical development with a topline readout expected in 1Q 2027 and BLA submission to follow." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926082897/tm2620295d1_ex99-1.htm)) |
| Q1 2027 | [OCU400 topline data readout](https://sec-api.dev/pdufa/ocu400) | OCGN |  | scheduled | "Ocugen is conducting the Phase 3 liMeliGhT clinical trial of OCU400, with topline data expected in the first quarter of 2027, followed by planned global regulatory submissions, including a Biologics License Application in the U.S." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926124836/tm2629434d1_ex99-1.htm)) |
| Q1 2027 | [Ocugen, Inc. topline data readout](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | scheduled | "FDA feedback confirmed that the path to rolling BLA submission remains tied to topline data expected in the first quarter of 2027, and the company is advancing preparation accordingly, including successfully completing Process Performance Qualification (PPQ) batches" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/tm2622368d1_ex99-1.htm)) |
| Feb to May 2027 | [Sub-retinal administration of ocu400-301 topline data readout](https://sec-api.dev/pdufa/sub-retinal-administration-of-ocu400-301) | OCGN | Retinitis Pigmentosa | scheduled | "NCT06388200 (A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-12 (ESTIMATED); Lead Sponsor Ocugen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388200)) |
| February 2027 | [Sub-retinal administration of ocu400-301 primary completion](https://sec-api.dev/pdufa/sub-retinal-administration-of-ocu400-301) | OCGN | Retinitis Pigmentosa | scheduled | "NCT06388200 (A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-12 (ESTIMATED); Lead Sponsor Ocugen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388200)) |
| Q2 2027 | [Ocugen, Inc. topline data readout](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | scheduled | "Topline data from the Phase 2/3 pivotal confirmatory trial (N=63 subjects) are anticipated in the second quarter of 2027, with a planned" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926122401/tm2628896d1_ex99-1.htm)) |
| Q2 2027 | [Ocugen, Inc. topline data readout](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | scheduled | "We completed enrollment in the Phase 2/3 pivotal confirmatory trial (N=63 subjects) early, in just nine months, and expect topline Phase 3 results in the second quarter of 2027, followed by a BLA submission in mid-2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1372299/000162828026069835/ocgn-20260930.htm)) |
| Q2 2027 | [Ocugen, Inc. topline data readout](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | scheduled | "Q2 2027 topline data expected;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926122401/tm2628896d1_ex99-2.htm)) |
| Jul to Oct 2028 | [OCU410 topline data readout](https://sec-api.dev/pdufa/ocu410) | OCGN | Dry Age-related Macular Degeneration | scheduled | "NCT07770828 (Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-30 (ESTIMATED); Lead Sponsor Ocugen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07770828)) |
| July 2028 | [OCU410 primary completion](https://sec-api.dev/pdufa/ocu410) | OCGN | Dry Age-related Macular Degeneration | scheduled | "NCT07770828 (Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-30 (ESTIMATED); Lead Sponsor Ocugen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07770828)) |

## Drugs

- [OCU200](https://sec-api.dev/pdufa/ocu200): 
- [OCU400](https://sec-api.dev/pdufa/ocu400): 
- [OCU410](https://sec-api.dev/pdufa/ocu410): Dry Age-related Macular Degeneration
- [OCU410ST](https://sec-api.dev/pdufa/ocu410st): Stargardt Disease
- [OCU500](https://sec-api.dev/pdufa/ocu500): 
- [Sub-retinal administration of ocu400-301](https://sec-api.dev/pdufa/sub-retinal-administration-of-ocu400-301): Retinitis Pigmentosa

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ocgn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OCGN catalysts: Ocugen, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ocgn/catalysts

```bibtex
@misc{secapidev_companies_ocgn_catalysts_20261116,
  title        = {OCGN catalysts: Ocugen, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ocgn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ocgn_catalysts_20261116","title":"OCGN catalysts: Ocugen, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ocgn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
